Lantern Pharma

Update in progress

LTRN (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Lantern Pharma Inc focuses on discovery and development of oncology drugs. Its pipeline includes LP-300 in Phase 2 for never-smokers with NSCLC adenocarcinoma; LP-184 in Phase 1a for advanced/metastatic solid tumors and CNS cancers; and LP-284 in Phase 1 for non-Hodgkin lymphomas. STAR-001 is preclinical for glioblastoma and other CNS cancers. It also runs an ADC program and AI-driven collaborations with Oregon Therapeutics (XCE853), TTC Oncology (TTC-352), and Actuate Therapeutics. Based in Dallas, TX.

Company score

Sentiment: 0.29; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.15; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.02; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.05; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.17; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive